Search Results - "Grob, JJ"

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma by Tawbi, Hussein A, Schadendorf, Dirk, Lipson, Evan J, Ascierto, Paolo A, Matamala, Luis, Castillo Gutiérrez, Erika, Rutkowski, Piotr, Gogas, Helen J, Lao, Christopher D, De Menezes, Juliana Janoski, Dalle, Stéphane, Arance, Ana, Grob, Jean-Jacques, Srivastava, Shivani, Abaskharoun, Mena, Hamilton, Melissa, Keidel, Sarah, Simonsen, Katy L, Sobiesk, Anne Marie, Li, Bin, Hodi, F. Stephen, Long, Georgina V

“…Two defined immune checkpoints have been exploited for cancer treatment. LAG-3 is a third immune checkpoint that blocks lymphocyte activation. Relatlimab, a…”
Get full text

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study by Long, G.V., Flaherty, K.T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalà, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J.B.A.G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M.A., Lane, S.R., Legos, J.J., Mookerjee, B., Grob, J.-J.

“…Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall survival (OS) with combination dabrafenib and…”
Get full text

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial by Long, Georgina V, MD, Stroyakovskiy, Daniil, MD, Gogas, Helen, MD, Levchenko, Evgeny, MD, de Braud, Filippo, MD, Larkin, James, FRCP, Garbe, Claus, Prof, Jouary, Thomas, MD, Hauschild, Axel, Prof, Grob, Jean-Jacques, Prof, Chiarion-Sileni, Vanna, MD, Lebbe, Celeste, Prof, Mandalà, Mario, MD, Millward, Michael, Prof, Arance, Ana, MD, Bondarenko, Igor, Prof, Haanen, John B A G, Prof, Hansson, Johan, Prof, Utikal, Jochen, Prof, Ferraresi, Virginia, MD, Kovalenko, Nadezhda, Prof, Mohr, Peter, MD, Probachai, Volodymr, MD, Schadendorf, Dirk, Prof, Nathan, Paul, MD, Robert, Caroline, MD, Ribas, Antoni, Prof, DeMarini, Douglas J, PhD, Irani, Jhangir G, MA, Swann, Suzanne, PhD, Legos, Jeffrey J, PhD, Jin, Fan, MD, Mookerjee, Bijoyesh, MD, Flaherty, Keith, MD

“…Summary Background Previously, a study of ours showed that the combination of dabrafenib and trametinib improves progression-free survival compared with…”
Get full text

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma by Long, Georgina V, Stroyakovskiy, Daniil, Gogas, Helen, Levchenko, Evgeny, de Braud, Filippo, Larkin, James, Garbe, Claus, Jouary, Thomas, Hauschild, Axel, Grob, Jean Jacques, Chiarion Sileni, Vanna, Lebbe, Celeste, Mandalà, Mario, Millward, Michael, Arance, Ana, Bondarenko, Igor, Haanen, John B.A.G, Hansson, Johan, Utikal, Jochen, Ferraresi, Virginia, Kovalenko, Nadezhda, Mohr, Peter, Probachai, Volodymyr, Schadendorf, Dirk, Nathan, Paul, Robert, Caroline, Ribas, Antoni, DeMarini, Douglas J, Irani, Jhangir G, Casey, Michelle, Ouellet, Daniele, Martin, Anne-Marie, Le, Ngocdiep, Patel, Kiran, Flaherty, Keith

“…The addition of a MEK inhibitor to a BRAF inhibitor improved response rates by nearly 16 percentage points (from 51% to 67%) and improved progression-free…”
Get full text

Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial by Basset-Seguin, Nicole, Prof, Hauschild, Axel, Prof, Grob, Jean-Jacques, Prof, Kunstfeld, Rainer, Prof, Dréno, Brigitte, Prof, Mortier, Laurent, Prof, Ascierto, Paolo A, Prof, Licitra, Lisa, MD, Dutriaux, Caroline, MD, Thomas, Luc, Prof, Jouary, Thomas, MD, Meyer, Nicolas, MD, Guillot, Bernard, Prof, Dummer, Reinhard, Prof, Fife, Kate, MD, Ernst, D Scott, Prof, Williams, Sarah, MSc, Fittipaldo, Alberto, MD, Xynos, Ioannis, MD, Hansson, Johan, Prof

“…Summary Background The Hedgehog pathway inhibitor vismodegib has shown clinical benefit in patients with advanced basal cell carcinoma and is approved for…”
Get full text

Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery by Gaudy-Marqueste, C., Dussouil, A.S., Carron, R., Troin, L., Malissen, N., Loundou, A., Monestier, S., Mallet, S., Richard, M.A., Régis, J.M., Grob, J.J.

“…Targeted therapy (TT) and immunotherapies (ITs) have dramatically improved survival in metastatic melanoma (MM). However, their efficacy on brain metastasis…”
Get full text

Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort by Kandel, M., Allayous, C., Dalle, S., Mortier, L., Dalac, S., Dutriaux, C., Leccia, M.T., Guillot, B., Saiag, P., Lacour, J.P., Legoupil, D., Lesimple, T., Aubin, F., Beylot-Barry, M., Brunet-Possenti, F., Arnault, J.P., Granel-Brocard, F., Stoebner, P.E., Dupuy, A., Maubec, E., Grob, J.J., Dreno, B., Rotolo, F., Ballon, A., Michiels, S., Lebbe, C., Borget, I.

“…Since 2011, significant progress was observed in metastatic melanoma (MM), with the commercialisation of seven immunotherapies or targeted therapies, which…”
Get full text

Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III by Grob, Jean Jacques, Schadendorf, Dirk, Lorigan, Paul, Ascierto, Paolo, Larkin, James, Nathan, Paul, Robert, Caroline, Hauschild, Axel, Weber, Jeffrey, Daud, Adil, Hamid, Omid, Dummer, Reinhard, Hansson, Johan, Hoeller, Christoph, Schachter, Jacob, Van Akkooi, Alexander C.J., Garbe, Claus

Get full text

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study by Long, G.V., Flaherty, K.T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalá, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J.B.A.G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M.A., Lane, S.R., Legos, J.J., Mookerjee, B., Grob, J.-J.

Get full text

More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments by Kandolf Sekulovic, L, Peris, K, Hauschild, A, Stratigos, A, Grob, J.-J, Nathan, P, Dummer, R, Forsea, A.-M, Hoeller, C, Gogas, H, Demidov, L, Lebbe, C, Blank, C, Olah, J, Bastholt, L, Herceg, D, Neyns, B, Vieira, R, Hansson, J, Rutkowski, P, Krajsova, I, Bylaite-Bucinskiene, M, Zalaudek, I, Maric-Brozic, J, Babovic, N, Banjin, M, Putnik, K, Weinlich, G, Todorovic, V, Kirov, K, Ocvirk, J, Zhukavets, A, Kukushkina, M, De La Cruz Merino, L, Ymeri, A, Risteski, M, Garbe, C

“…Abstract Background Despite the efficacy of innovative treatments for metastatic melanoma, their high costs has led to disparities in cancer care among…”
Get full text

Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study by Hansson, Johan, Bartley, Karen, Karagiannis, Thomas, Grob, Jean-Jacques, Kunstfeld, Rainer, Dréno, Brigitte, Mortier, Laurent, Ascierto, Paolo A., Licitra, Lisa, Dutriaux, Caroline, Thomas, Luc, Meyer, Nicolas, Guillot, Bernard, Dummer, Reinhard, Fife, Kate, Ernst, D. Scott, Yim, Yeun Mi, Dimier, Natalie, Fittipaldo, Alberto, Basset-Séguin, Nicole, Hauschild, Axel

“…Background Health-related quality of life (HRQoL) data are limited in patients with advanced basal cell carcinoma. Objectives To report HRQoL outcomes based on…”
Get full text

ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy by Butler, M.O., Robert, C., Negrier, S., In, G.K., Walker, J., Krajsova, I., Atkinson, V.G., Hansson, J., Kapiteijn, E., Loquai, C., Shaw, H.M., Cheng, T., Mansard, S., Grob, J.J., Guidoboni, M., Mehta, M., Ascierto, P.A., Diab, A.

Get full text

ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy by Butler, Marcus O., Robert, Caroline, Negrier, Sylvie, In, Gino Kim, Walker, John WT, Krajsova, Ivana, Atkinson, Victoria, Hansson, Johan, Kapiteijn, Ellen, Loquai, Carmen, Shaw, Heather May, Cheng, Tina, Mansard, Sandrine, Grob, Jean Jacques, Guidoboni, Massimo, Mehta, Minal, Ascierto, Paolo Antonio, Diab, Adi

“…Abstract only TPS9599 Background: Tilsotolimod (IMO-2125) is a Toll-like receptor (TLR) 9 agonist with potent immunostimulating activity. In an ongoing Phase…”
Get full text

Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study by AVRIL, M. F, AAMDAL, S, PORTA, V. Guillem, FRA, J, BONNETERRE, J, SAÏAG, P, KAMANABROU, D, PEHAMBERGER, H, SUFLIARSKY, J, GONZALEZ LARRIBA, J. L, SCHERRER, A, MENU, Y, GROB, J. J, HAUSCHILD, A, MOHR, P, BONERANDI, J. J, WEICHENTHAL, M, NEUBER, K, BIEBER, T, GILDE, K

“…To compare fotemustine and dacarbazine (DTIC) in terms of overall response rate (ORR) as primary end-point and overall survival, duration of responses, time to…”
Get full text

Assessment of quality of life (QoL) using Skindex-16 in patients (pts) with locally advanced basal cell carcinoma (laBCC) treated with vismodegib (VISMO) in the STEVIE study by Grob, JJ, Bartley, K, Kuntsfeld, R, Dreno, B, Mortier, L, Ascierto, PA, Dutriaux, C, Meyer, N, Guillot, B, Dummer, R, Williams, S, Fittipaldo, A, Ernst, DS, Hauschild, A, Basset-Seguin, N, Hansson, J

Get full text

Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma by MIDDLETON, M. R, GROB, J. J, DRENO, B, HENZ, M, SCHADENDORF, D, KAPP, A, WEISS, J, FRAASS, U, STATKEVICH, P, MULLER, M, THATCHER, N, AARONSON, N, FIERLBECK, G, TILGEN, W, SEITER, S, GORE, M, AAMDAL, S, CEBON, J, COATES, A

“…To compare, in 305 patients with advanced metastatic melanoma, temozolomide and dacarbazine (DTIC) in terms of overall survival, progression-free survival…”
Get full text

Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life by Grob, J.J., Revuz, J., Ortonne, J.P., Auquier, P., Lorette, G.

“…Summary Background  A better management of chronic skin disorders (CSDs) requires a knowledge of their impact from the patient's point of view. Objectives  To…”
Get full text

Adjuvant interferon alfa in malignant melanoma: An interdisciplinary and multinational expert review by Ascierto, Paolo A, Gogas, Helen J, Grob, Jean Jacques, Algarra, Salvador Martín, Mohr, Peter, Hansson, Johan, Hauschild, Axel

“…Abstract Interferon alfa (IFNα) and pegylated IFNα2b (PegIFNα2b) are the only agents currently approved for the adjuvant treatment of resected melanoma at high…”
Get full text

Superiority of a cognitive education with photographs over ABCD criteria in the education of the general population to the early detection of melanoma: A randomized study by Girardi, Sophie, Gaudy, Caroline, Gouvernet, Joanny, Teston, Jacques, Richard, Marie Aleth, Grob, Jean‐Jacques

“…Most education campaigns for melanoma (MM) detection in the general population have used the “ABCD” algorithm, although recognition of objects in the real life…”
Get full text

Randomized Clinical Trials for Psoriasis 1977–2000: The EDEN Survey by Naldi, Luigi, Svensson, Ake, Diepgen, Thomas, Elsner, Peter, Grob, Jean-Jacques, Coenraads, Pieter-Jan, Bavinck, Jan Nico Bouwes, Williams, Hywel

“…This study aims to describe the range of treatment comparisons, study designs and quality of reporting of randomized clinical trials (RCTs) in psoriasis…”
Get full text